Quick Answer
NEPHROS INC reported Cash and Equivalents of $5.40 million for fiscal year 2025.
NEPHROS INC Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $5.40M | +43.6% |
| 2024 | $3.76M | -12.7% |
| 2023 | $4.31M | +18.5% |
| 2022 | $3.63M | -47.9% |
| 2021 | $6.97M | -15.5% |
| 2020 | $8.25M | +98.0% |
| 2019 | $4.17M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $5.17M | +110.5% | +1.9% |
| June 30, 2025 | $5.07M | +64.7% | +24.3% |
| March 31, 2025 | $4.08M | +12.3% | +8.5% |
| December 31, 2024 | $3.76M | -12.7% | +53.0% |
| September 30, 2024 | $2.46M | -46.8% | -20.2% |
| June 30, 2024 | $3.08M | -24.1% | -15.2% |
| March 31, 2024 | $3.63M | -5.3% | -15.6% |
| December 31, 2023 | $4.31M | +18.5% | -6.8% |
- NEPHROS INC showed an increase of +43.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2025 period, NEPHROS INC’s cash and equivalents has grown by 29.6% (from $4.17 million to $5.40 million).
- The most recent figure is from NEPHROS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: